CNTX
Context Therapeutics Inc
NASDAQ: CNTX · HEALTHCARE · BIOTECHNOLOGY
$0.21
-9.97% today
Updated 2026-10-28
Market cap
$22.40M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.48
Dividend yield
—
52W range
$0 – $4
Volume
1.4M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →271 stocks currently score above 75
Price targets
Analyst target
$4.03
+1808.19%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z 1.17 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.04M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-14.84M | $-23.96M | $-26.73M | $-36.12M | $-14.56M |
| EPS | — | — | — | — | $-0.48 |
| Free cash flow | $-14.09M | $-21.05M | $-29.31M | $-26.42M | $-7.04M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Context Therapeutics Inc trades at $0.21. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 1.17, it sits in the distress.
Frequently asked questions
What is Context Therapeutics Inc's stock price?
Context Therapeutics Inc (CNTX) trades at $0.21.
Is Context Therapeutics Inc overvalued?
Context Therapeutics Inc carries a Smart Value Score of 30/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Context Therapeutics Inc (CNTX)?
The 12-month analyst consensus target is $4.03, about 1808.2% above the current $0.21. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Context Therapeutics Inc's Altman Z-Score is 1.17, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-77.06%
Beta1.72
50D MA$0.37
200D MA$1.51
Shares out0.09B
Float0.06B
Short ratio—
Avg volume1.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—